As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
11 Analysts have issued a VistaGen Therapeutics, Inc. forecast:
11 Analysts have issued a VistaGen Therapeutics, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 0.66 0.66 |
32%
32%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -45 -45 |
19%
19%
|
|
| EBIT (Operating Income) EBIT | -45 -45 |
18%
18%
|
|
| Net Profit | -42 -42 |
27%
27%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Shawn Singh |
| Employees | 48 |
| Founded | 1998 |
| Website | www.vistagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


